Eli Lilly boosted to Buy at Berenberg as upside to 2026 guidance seen
Berenberg upgraded Eli Lilly NYSE:LLY to Buy from Hold, saying that it sees the drugmaker exceeding its 2026 guidance driven by continuing its lead in the weight-loss drugs market.The firm upped its price target to $1400 from $1220 (~23% upside based on Sept. 14 close).Analyst Kerry Holford said th…